AlphAIAlphAI — Financial news for AI agents
rttnews.comNOV 42 min read$PODD

Insulet Q3 Net Income Rises; Issues FY26 Outlook

Insulet (PODD) reported Q3 net income of $141.1M, up from $87.6M YoY, with revenue at $842.0M, a 19.2% increase. Adjusted EPS rose 59.9% to $1.99. The company raised FY26 revenue growth guidance to 21-22% from 20-22%. Shares fell 4.43% in pre-market trading.

Original reporting
rttnews.com
Published Nov 4, 2026, 1:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 1:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Insulet Q3 Net Income Rises; Issues FY26 Outlook — source image
Source · rttnews.com
Decision brief

The 30-second read

$PODDBullishHigh
01

Why it matters

The earnings beat and guidance revision are fresh, material information that moved the stock down 4.4% pre‑market.

02

Market read

New earnings and guidance provide a clear trading signal for PODD; sector peers may be re‑rated.

03

What to watch

Insulet's strong Omnipod revenue growth and constant‑currency performance may offset guidance concerns.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Insulet (NASDAQ: PODD) released its third‑quarter 2026 results, showing higher profit and revenue but narrowing FY26 outlook.

Company-level read

Ticker impact

$PODDBullishHigh confidence
Context

Insulet reported Q3 net income of $141.1M and revised FY26 revenue growth guidance, with shares down 4.43% pre‑market.

Expected impact

likely continued pressure as investors price in the reduced FY26 growth range

Evidence & confidence

The earnings release provides fresh numbers and a guidance cut, which historically triggers short‑term downside.

Market effects

Sector

May weigh on the broader diabetes device sector as peers' guidance is compared.

Regional

U.S. healthcare stocks could see modest pullback.

Global

Limited; impact confined to U.S. med‑tech investors.

Counterpoint

What could challenge this read

The earnings beat could support a bounce if the market overreacts to the guidance tweak.

Key entities

  • company
    Insulet

    U.S. listed medical device maker of the Omnipod insulin‑delivery system.

Read at source← All news

StoryInsulet reports Q3 2026 earnings beat with higher revenue and EPS

Also covered by

2 outlets

Related articles

NOV 4
$PODDHighAI 8/10

Insulet: Q3 Earnings Snapshot

Insulet Corp. (PODD) reported Q3 net income of $141.1M, or $2.03 per share, beating analyst estimates of $1.59 per share. Revenue was $842M, exceeding expectations of $833.3M. The company makes insulin infusion systems.

finance.yahoo.com2 min
NOV 4
$PODDHigh

Insulet Reports Third Quarter 2026 Results

INSULET CORP (PODD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Insulet Reports Third Quarter 2026 Results Third Quarter Revenue of $842 million, Increase of 19.2% (19.6% in Constant Currency 1 ) ACTON, Mass. - November 4, 2026 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pu

SEC EDGAR 8-K2 min
SEP 14
$RMDMedAI 8/10

Patient Monitoring Stocks Q2 Teardown: ResMed (NYSE:RMD) Vs The Rest

ResMed (RMD) and peers reported Q2 earnings, with revenues beating estimates by 1.4% but next quarter's guidance below. RMD's revenue grew 8.6% YoY, meeting expectations, while iRhythm (IRTC) saw 20.1% growth, exceeding estimates. Insulet (PODD) and DexCom (DXCM) also reported, with mixed results. Stocks have declined since earnings, with RMD down 2.3% and IRTC down 13%.

yahoo.com3 min